Connect Biopharma Holdings Limited (NASDAQ: CNTB) reported a widening net loss for the second quarter of 2026, driven by increased research and development expenses associated with its Phase 2 clinical trials. The clinical-stage biopharmaceutical company recorded a net loss of $17.3 million for the three months ended June 30, 2026, compared to a net loss of $12.9 million in the corresponding period of 2025.

Despite the expanded loss, the company generated significant license and collaboration revenues of $2.8 million in Q2 2026, a sharp increase from $48,000 in Q2 2025. This revenue was primarily attributed to a regulatory-based milestone payment from its partner Simcere Pharmaceutical Co., Ltd., net of development cost sharing. For the first half of 2026, total license and collaboration revenues reached $2.9 million.

Financial Performance

The company’s operating expenses rose significantly year-over-year as it advanced its lead candidate, rademikibart. Research and development expense for the quarter totaled $16.3 million, up from $8.8 million in Q2 2025. This increase was driven by costs related to the initiation of the Phase 2 Seabreeze STAT asthma and COPD studies in May 2025.

General and administrative expenses declined to $4.1 million from $4.7 million in the prior year quarter, largely due to lower professional fees following one-time costs incurred in previous periods to support U.S.-centric operational efforts. This reduction was partially offset by an increase in non-cash share-based compensation.

What the Numbers Show

The financial data reveals a distinct divergence between revenue generation and operational burn. While license revenue surged due to a discrete milestone event, the underlying operating loss widened by approximately 31% year-over-year. The company’s cash position declined to $31.5 million as of June 30, 2026, down from $44.3 million at the end of December 2025. Management stated that this cash runway is expected to extend for at least one year from the date of the release, supporting continued execution of the development program without immediate need for external capital.

Clinical Development Updates

Connect Biopharma announced the completion of enrollment in both its Phase 2 Seabreeze STAT asthma and COPD studies. These trials evaluate rademikibart as an adjunct treatment for acute exacerbations in patients with type 2 inflammation. Topline results from both studies are expected in September 2026.

Following the release of these data, the company plans to engage with the U.S. Food and Drug Administration (FDA) to align on a potential Phase 3 program. Additionally, in August 2026, Connect initiated the Phase 2 Seabreeze STAT IV study, an open-label trial evaluating intravenous rademikibart in 40 participants. This study aims to bridge subcutaneous and IV administration routes for treating acute exacerbations.

Piper Sandler analyst Biren Amin has initiated coverage on Connect Biopharma Hldgs with an Overweight rating and announced a price target of $7. The rating suggests a positive outlook for the NASDAQ-listed company, which trades under the ticker CNTB. The price target provides a specific valuation benchmark for investors monitoring the stock's performance.

Analyst Details

The coverage initiation comes from Biren Amin, an analyst at Piper Sandler. The firm's Overweight rating indicates that the stock is expected to outperform the average return of the analyst's coverage universe over the next 12 to 18 months.

Key Metrics